PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-90.13%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-148.93%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-24.41%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-24.41%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-24.71%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-23.33%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-23.33%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.59%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
10.68%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1874.89%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
89.77%
5Y OCF/share CAGR above 1.5x AGEN's 51.86%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
79.09%
3Y OCF/share CAGR 1.25-1.5x AGEN's 69.74%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
-5123.81%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
89.73%
5Y net income/share CAGR above 1.5x AGEN's 15.15%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
77.51%
3Y net income/share CAGR above 1.5x AGEN's 35.16%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1605.51%
10Y equity/share CAGR above 1.5x AGEN's 325.47%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-64.94%
Negative 5Y equity/share growth while AGEN is at 129.78%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
48.08%
Below 50% of AGEN's 109.44%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
Negative asset growth while AGEN invests at 6.47%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.40%
We have a declining book value while AGEN shows 29.31%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-26.37%
We’re deleveraging while AGEN stands at 6.76%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
15.04%
We increase R&D while AGEN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
33.15%
SG&A growth well above AGEN's 2.74%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.